



Prior Authorization Approval Criteria
Department of Pharmacy Services

Generic Name: Famotidine 40 mg and Suspension

Brand Name: Pepcid

Medication	Availability	Formulary Status
Chewable 10mg	OTC	Not a covered Benefit
Famotidine* 20mg	Rx	Not a covered Benefit
Famotidine 40mg	Rx	Formulary
Pepcid AC10 mg	OTC	Not a covered Benefit
Pepcid AC Max Str 20mg	OTC	Not a covered Benefit
Pepcid* 20mg (ODT & regular)	Rx	Not a covered Benefit
Pepcid 40mg	Rx	Formulary
Pepcid Suspension	Rx	Formulary

*Pepcid 20mg is available over the counter and as such is not a covered benefit.

Medication Class: H2 antagonist

FDA Approved Uses:

- Short term treatment of active duodenal ulcer, active benign gastric ulcer, gastroesophageal reflux disease (GERD), esophagitis due to GERD including erosive or ulcerative disease.
- Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer.
- Treatment of pathological hypersecretory conditions (i.e. Zollinger-Ellison Syndrome, multiple endocrine adenomas)

Usual Doses:

- Duodenal Ulcer
 - Acute Therapy: 40 mg once a day at bedtime for 4-8 weeks
 - Maintenance Therapy: 20 mg once a day at bedtime
- Benign Gastric Ulcer
 - Acute Therapy: 40 mg once a day at bedtime.
- Gastroesophageal reflux disease (GERD):
 - 20 mg BID for 6 weeks.
- Esophagitis including ulcerations, erosions and accompanying symptoms due to GERD:
 - 20 mg – 40 mg bid for up to 12 weeks.
- Zollinger-Ellison Syndrome:
 - 20-160 mg every 6 hours. Dosage should be adjusted to individual patient needs.



Prior Authorization Approval Criteria, *continued*

Generic Name: Famotidine 40 mg and Suspension

Brand Name: Pepcid

Duration of Therapy:

- Duodenal Ulcer
 - Acute Therapy: Most patients heal within 4 weeks; there is rarely reason to use Pepcid at full dosage for longer than 6-8 weeks.
 - Maintenance Therapy: Indefinite
- Benign Gastric Ulcer
 - Acute Therapy: 6-8weeks
- Gastroesophageal reflux disease (GERD):
 - 6 weeks
- Esophagitis including ulcerations, erosions and accompanying symptoms due to GERD:
 - Up to 12 weeks
- Zollinger-Ellison Syndrome:
 - Continue as long as clinically indicated.

Guidelines for Approval for Adults:

- Failed/intolerant to ranitidine and cimetidine.
- Clinically documented GERD, gastritis, esophagitis, duodenal or gastric ulcer, or a pathological hypersecretory condition.
- Failed/intolerant to OTC Pepcid

Guidelines for Approval for Children:

- Failed/intolerant to ranitidine.
- Clinically documented GERD, gastritis, esophagitis, duodenal or gastric ulcer, or a pathological hypersecretory condition.
- If the request is for Pepcid in tablet formulation the patient must have failed or is intolerant to OTC Pepcid.

Not approved if:

- The patient does not meet the above stated criteria.



P&T Approval: _____ Date: _____